STOCK TITAN
  1. Home
  2. Sec-filings
  3. TENKU
  4. [424B4] TenX Keane Acquisition Unit Prospectus Filed Pursuant to Rule 424(b)(4)

[424B4] TenX Keane Acquisition Unit Prospectus Filed Pursuant to Rule 424(b)(4)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B4

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock TENKU logo
TenX Keane Acquisition

NASDAQ:TENKU

TENKU Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

TENKU Latest News

Aug 9, 2024
TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update
Aug 5, 2024
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
Jan 10, 2024
TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment Proposal
Jan 2, 2024
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Oct 24, 2023
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

TENKU Latest SEC Filings

Sep 2, 2025
[S-3] TenX Keane Acquisition Unit Shelf Registration Statement
Aug 18, 2025
[8-K] TenX Keane Acquisition Unit Reports Material Event
Aug 12, 2025
[8-K] TenX Keane Acquisition Unit Reports Material Event
Aug 12, 2025
[10-Q] TenX Keane Acquisition Unit Quarterly Earnings Report
Aug 7, 2025
[Form 4] TenX Keane Acquisition Unit Insider Trading Activity

TENKU Stock Data

8.55M
4.41%
0%
Shell Companies
Pharmaceutical Preparations
Link
United States
NEW YORK